Autoimmune encephalitis (AE) is an emerging group of autoimmune or paraneoplastic diseases with complex neuropsychiatric presentations. Patients often present primarily or even solely with psychiatric symptoms such as fulminant psychosis, and as such, awareness amongst mental health practitioners is paramount in identification and timely treatment.
Currently, limited exposure and knowledge of these disorders for providers in many disciplines leads to delays in appropriate diagnostic evaluation and management. Our goal is to raise awareness and enhance knowledge as to how to initiate testing and appropriately manage suspected cases – psychiatrists and psychiatric providers will certainly be an integral component of this process.
While reports and descriptions of AE date back to the 1960s, our understanding of this entity has expanded dramatically over the past 15 years with the recognition and identification of pathogenic, neuronal autoantibodies. In 2005, Dr. Josep Dalmau and his team first described anti-N-methyl-D-aspartate (NMDA) receptor encephalitis, a neuropsychiatric disorder of proven autoimmune etiology that almost universally presents with psychosis.
Since that time, many more neuronal autoantibodies associated with AE have been described, and clinical criteria have been published to guide clinicians in making a diagnosis of AE prior to receiving autoantibody panel results or in the event that no autoantibody is detected. The spectrum of psychiatric symptoms that may be seen with AE now includes changes in behavior (e.g., agitation and aggression) or mood, hallucinations, delusions, mutism, and disorganized thinking.
Complementing this research has been increasing evidence for an inflammatory basis to many other neuropsychiatric disorders, particularly those of psychosis such as schizophrenia, in which complement C4 involvement has been implicated. While there is currently limited direct evidence for specific inflammatory mechanisms and no clear biomarkers of prognosis in individuals with schizophrenia or at clinical high risk for psychosis, there is extensive research being undertaken in these areas.
Despite the improved awareness that autoimmune mechanisms may underlie the development of neuropsychiatric illnesses, there remains a lot that we do not know. Autoantibodies against neuronal receptors have been identified in the systemic circulation of patients with presumed primary psychiatric disorders, however, the significance of this finding and whether they play a pathophysiologic role remains unclear. Additionally, there is no clear consensus regarding which patients with predominantly psychiatric symptoms warrant further investigations for an autoantibody or other autoimmune cause.
Psychiatrists play a pivotal role in the diagnosis and treatment of AE. As psychiatric symptoms often dominate the symptoms that occur at onset of this disease, patients may present initially to a psychiatrist who are tasked with identifying abnormal features of psychosis presentations, including alterations in mental status, seizures, and dysautonomia, which may prompt consideration of AE and consultation with a neurologist. Furthermore, for patients with suspected AE undergoing immunotherapy, psychiatric symptoms are frequently ongoing and may require symptomatic pharmacologic and non-pharmacologic symptoms.
The Autoimmune Encephalitis Alliance is dedicated to raising awareness of AE and recognizes the importance of a multi-disciplinary approach to the diagnosis and management of these patients, which includes psychiatrists in addition to neurologists and rheumatologists. What follows is a compilation of scientific articles that may be of specific interest to psychiatrists, and we invite you to join us on this mission to increase awareness of AE and to improve the care provided and outcomes for individuals with this disease.
– Anusha K. Yeshokumar, MD | Pojen Deng, MD
Publications on Autoimmune Encephalitis with a focus on Psychiatry
Pollak TA, Lennox BR, Vincent A, Najjar S, Bechter K
Lancet Psychiatry. 2020 Jan;7(1):93-108.
There is increasing recognition in the neurological and psychiatric literature of patients with so-called isolated psychotic presentations who have tested positive for neuronal autoantibodies and who have responded to immunotherapies. Although these individuals are sometimes described as having atypical, mild, or attenuated forms of autoimmune encephalitis, some authors feel that that these cases are sufficiently different from typical autoimmune encephalitis to establish a new category of so-called autoimmune psychosis. We briefly review the background, discuss the existing evidence for a form of autoimmune psychosis, and propose a novel, conservative approach to the recognition of possible, probable, and definite autoimmune psychoses for use in psychiatric practice.
Al-Diwani A, Irani SR
Lancet Psychiatry. 2019 Mar;6(3):235-246.
Early immunotherapy administration improves outcomes in patients with N-methyl-D-aspartate receptor (NMDAR)-antibody encephalitis. As most patients with NMDAR-antibody encephalitis present to psychiatrists, the psychopathology of NMDAR-antibody encephalitis needs to be clearly defined to encourage accurate clinical identification and prompt treatment.
Mooneyham GC, Gallentine W, Van Mater H.
Child Adolesc Psychiatr Clin N Am. 2018 Jan;27(1):37-52.
Medical conditions that present with psychiatric symptoms are becoming increasingly well-recognized in response to the emergence of the field of neuroimmunology. As the availability of testing for novel antineuronal antibodies has increased, so too has the clinical awareness of this diagnostic spectrum.
In the clinic: autoimmune encephalitis
Neurology Today. 2018 June 7;18(11):16-17.
Researchers found that children and adolescents had persistent neuropsychological and behavioral problems even after recovery from pediatric anti-NMDAR encephalitis, which should be monitored and treated.
Autoimmune encephalitis and psychiatric disorders
Honnorat and Plazat
Revue Neurol. 2018; 174:228–36.
Autoimmune encephalitis (AE) refers to a rare, newly described, group of diseases associated with specific circulating autoantibodies directed against neuronal proteins used as biomarkers of the disease. As psychiatric symptoms may predominate at the onset or over the course of these diseases, the diagnosis is frequently delayed. Yet, patients’ prognoses depend on the speed with which the disease is detected, identified and managed.
Dalmau and Graus
N Engl J Med. 2018 Mar 1;378(9):840-851.
The category of autoimmune encephalitides constitutes disorders with relatively distinct characteristics such as psychosis, seizures, abnormal movements, coma, and dysautonomia. Specific autoantibodies can be identified, and the disorders can be successfully treated.
Najjar et al.
J Neuroinflammation. 2018;15:40.
Growing data point to the overlap between psychosis and pathological processes associated with immunological dysregulation as well as inflammation. Notably, the recent discovery of antibodies against synaptic and neuronal cell membrane proteins such as anti-N-methyl-d-aspartate receptor provides more direct evidence of the etiological connection between autoimmunity and subsequent hazard of psychosis.
Dale, R, Gorman M, Lim M.
Curr Opin Neurol. 2017 Jun; 30(3):334-344.
Auto-antibodies that bind to conformational extracellular epitopes of neuronal receptors or synaptic proteins have provided clinicians with essential biomarkers in acute neurology. This review summarizes the current status and challenges in the field.
Ellul P et al.
Frontiers in Psychiatry. 2017 April;8:54.
Schizophrenia is a heterogeneous and complex psychiatric disorder affecting up to 1% of the population worldwide. Although the precise development of schizophrenia is not yet fully understood, it is now admitted to be underpinned by the entanglement of genetic, environmental, and immuno-inflammatory factors.
Herken et al
Front Psychiatry. 2017 Feb 16;8:25.
Autoimmune mechanisms causing diverse psychiatric symptoms are increasingly recognized and brought about a paradigm shift in neuropsychiatry. Identification of underlying antibodies against neuronal ion channels or receptors led to the speculation that a number of patients go misdiagnosed with a primary psychiatric disease.
Psychosomatics. 2017 May-Jun;58(3):228-244.
To provide a critical review of autoimmune encephalopathy—broadly defined as neuropsychiatric features directly related to an autoimmune process—relevant for psychiatric practice.
J Clin Neurol. 2016 Jan; 12(1): 1-13.
Autoimmune encephalitis causes subacute deficits of memory and cognition, often followed by suppressed level of consciousness or coma. A careful history and examination may show early clues to particular autoimmune causes, such as neuromyotonia, hyperekplexia, psychosis, dystonia, or the presence of particular tumors.
Maccaferri et al
Brain Disord Ther 2016 May; 5(2):215
Anti-N-methyl-D-aspartate receptor encephalitis is a relatively newly identified autoimmune neuropsychiatric disorder that predominantly affects children and young adults. Although psychiatric symptoms are highly prevalent and frequently severe, it has mainly been reported in neurological, but not psychiatric, literature. Understanding this form of encephalitis, its quick diagnosis and which treatment to provide are of utmost importance for consultation-liaison psychiatrists.
Graus F, Titulaer MJ, et al.
Lancet Neurology 2016 Apr; 15(4):391-404
Encephalitis is a severe inflammatory disorder of the brain with many possible causes and a complex differential diagnosis. Advances in autoimmune encephalitis research in the past 10 years have led to the identification of new syndromes and biomarkers that have transformed the diagnostic approach to these disorders. However, existing criteria for autoimmune encephalitis are too reliant on antibody testing and response to immunotherapy, which might delay the diagnosis.
Bost et al.
Neuropsychiatr Dis Treat. 2016; 12: 2775–2787.
Autoimmune encephalitis is a rare and newly described group of diseases involving autoantibodies directed against synaptic and neuronal cell surface antigens. As neurological symptoms are fairly well described in the literature, this review focuses on the nature of psychiatric symptoms occurring at the onset or during the course of the diseases.
Kruse et al
Annals of Clinical Psychiatry. 2014 Feb;26(1):e1-9
Anti-N-methyl-d-aspartate receptor encephalitis was formally described in 2007 and includes a range of psychiatric and neurologic symptoms. Most patients with anti-NMDAR encephalitis initially present to psychiatrists for diagnosis and treatment. However, there is limited literature summarizing treatment strategies for psychiatric symptoms. In an effort to improve identification and treatment, this review article provides an overview of anti-NMDAR encephalitis, with a focus on psycho- pharmacologic treatment strategies.
Leypoldt F, Wandinger K-P, Bien CG, Dalmau J.
European neurological review. 2013;8(1):31-37.
The term autoimmune encephalitis is used to describe a group of disorders characterised by symptoms of limbic and extra-limbic dysfunction occurring in association with antibodies against synaptic antigens and proteins localised on the neuronal cell surface. Since many patients respond well to immunosuppressive treatment, the recognition of these disorders is of utmost importance.
Titulaer MJ, McCracken L, et al.
Lancet Neurology; London 12.2 (Feb 2013): 157-65.
Anti-NMDA receptor encephalitis is an autoimmune disorder in which the use of immunotherapy and the long-term outcome have not been defined. We aimed to assess the presentation of the disease, the spectrum of symptoms, immunotherapies used, timing of improvement, and long-term outcome.
Dale et al
Brain. 2012 Nov;135(Pt11):3453-68.
Recent reports of autoantibodies that bind to neuronal surface receptors or synaptic proteins have defined treatable forms of autoimmune encephalitis. Despite these developments, many cases of encephalitis remain unexplained. We have previously described a basal ganglia encephalitis with dominant movement and psychiatric disease, and proposed an autoimmune aetiology. Given the role of dopamine and dopamine receptors in the control of movement and behaviour, we hypothesized that patients with basal ganglia encephalitis and other putative autoimmune basal ganglia disorders harboured serum autoantibodies against important dopamine surface proteins.
Zuliani et al.
J Neurol Neurosurg Psychiatry. 2012 June; 83(6): 638-645.
The concept of antibody mediated CNS disorders is relatively recent. The classical CNS paraneoplastic neurological syndromes are thought to be T cell mediated, and the onconeural antibodies merely biomarkers for the presence of the tumour. Over the past 10 years, identification of autoimmune forms of encephalitis with antibodies against neuronal surface antigens, particularly the voltage gated potassium channel complex proteins or the glutamate N-methyl-D-aspartate receptor, have shown that CNS disorders, often without associated tumours, can be antibody mediated and benefit from immunomodulatory therapies.
Kayser et al.
Curr Psychiatry Rev. 2011; 7(3):189-193.
Anti-NMDA receptor encephalitis is an autoimmune disorder in which antibodies attack NMDA (N-methyl-D-aspartate)-type glutamate receptors at central neuronal synapses. Symptoms include a highly characteristic set of neurologic deficits, but also prominent psychiatric manifestations that often bring mental health professionals into the course of care. Distinct phases of illness have become increasingly appreciated, and include a range of psychotic symptoms early in the course of the disease followed by more severe fluctuations in consciousness with neurologic involvement, and ultimately protracted cognitive and behavioral deficits. We provide an up to date review of this disorder and highlight the role of psychiatry in diagnosis, symptomatology, and treatment.